🔗 Share this article

While the US continues making historic adjustments to its vaccine guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccinations during the global health crisis and has concentrated on possible deaths after Covid vaccination in her recent time at the FDA.

Planned Overhauls to Childhood Vaccine Schedule

Agency leaders were set to announce radical revisions to the childhood immunization program in December, aligning the US with the Danish immunization schedule, sources say – a major change that would put the US out of step with a large portion of the world with insufficient data for public health gain. The announcement has been postponed until the next year.

Rather than the top vaccines chief, Dr. Høeg is set to address the audience at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A Shift at the Agency

This interim role could signify a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for discontinuing specific pediatric vaccine recommendations in the US to become more like Denmark, a nation with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccines – usually the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Qualifications

Dr. Høeg has little discernible track record in drug development, regulation or administrative roles, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the CDER, said a neurologist and psychiatrist. “She’s never run a clinical trial. She is not versed in running a major agency. She has no expertise in industry regulation.”

Previous heads of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she lacks the type of experience that prior appointees who led the center have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock emphasized.

“The public just zeroes in on the novel medication approvals, but the generic program clears a multitude of generic drugs. There’s a biosimilars division, OTC medication office and other areas, and each of these have to be looked after,” Dr. Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

There is also, a major administrative aspect to the job, which supervises more than 5,000 staff members. “It’s a massive management job, if you perform it correctly,” she said.

Official Statement and Disputed Policies

Regarding concerns about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among FDA leaders on immunizations, a press secretary responded that the “questions stem from flawed assumptions”.

“Her experience aligns with the functions of her job,” the representative said, noting the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg takes over the agency head's new expedited review system, a disputed one-day drug-approval program that apparently concerned her former heads. “How are these drugs being selected for this fast-track system? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards laxer regulations of all drugs, aside from immunizations.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a more established, if concerning, history, some experts observe. She published a research paper using unverified crowd-sourced reports to assess the frequency of heart inflammation following COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the incoming federal leadership encompassed revising rules for novel immunizations and halting “non-essential” immunizations, she said after the election on a podcast. At the FDA, Høeg has allegedly suggested barring teenage boys from getting COVID-19 vaccinations.

“She is an thorough ideologue who begins with her conclusions and tailors the evidence to accommodate the evidence in a extremely disingenuous, fraudulent fashion,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg became part of other skeptics, {like|